Huntsman Corporation

DB:HTR Stock Report

Market Cap: €3.2b

Huntsman Valuation

Is HTR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HTR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HTR (€18) is trading below our estimate of fair value (€49.7)

Significantly Below Fair Value: HTR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HTR?

Key metric: As HTR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HTR. This is calculated by dividing HTR's market cap by their current revenue.
What is HTR's PS Ratio?
PS Ratio0.6x
SalesUS$5.99b
Market CapUS$3.34b

Price to Sales Ratio vs Peers

How does HTR's PS Ratio compare to its peers?

The above table shows the PS ratio for HTR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.5x
LXS LANXESS
0.3x2.9%€2.1b
BAS BASF
0.6x4.5%€38.5b
WCH Wacker Chemie
0.6x5.2%€3.7b
SDF K+S
0.6x-0.02%€2.0b
HTR Huntsman
0.6x5.7%€3.3b

Price-To-Sales vs Peers: HTR is expensive based on its Price-To-Sales Ratio (0.6x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does HTR's PS Ratio compare vs other companies in the DE Chemicals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
2HRA H&R GmbH KGaA
0.1x2.7%US$135.97m
NSAK OTI Greentech
0.03xn/aUS$743.21k
B7Y Byotrol
0.04xn/aUS$246.97k
No more companies available in this PS range
HTR 0.6xIndustry Avg. 1.0xNo. of Companies6PS00.40.81.21.62+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HTR is good value based on its Price-To-Sales Ratio (0.6x) compared to the European Chemicals industry average (1.1x).

Price to Sales Ratio vs Fair Ratio

What is HTR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HTR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: HTR is expensive based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HTR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€18.00
€22.46
+24.8%
9.3%€27.22€18.77n/a14
Nov ’25€20.00
€23.55
+17.8%
8.0%€26.86€21.30n/a14
Oct ’25€21.40
€22.14
+3.5%
10.6%€26.06€18.87n/a14
Sep ’25€19.60
€22.15
+13.0%
10.6%€26.07€18.87n/a14
Aug ’25€21.80
€24.59
+12.8%
7.8%€27.61€21.17n/a14
Jul ’25€20.80
€25.40
+22.1%
7.5%€29.87€22.40n/a14
Jun ’25€22.40
€25.25
+12.7%
8.7%€29.63€20.37n/a15
May ’25€22.60
€25.80
+14.2%
9.5%€30.06€20.67n/a15
Apr ’25€23.60
€25.36
+7.4%
10.3%€30.39€20.26n/a15
Mar ’25€23.40
€25.19
+7.7%
10.7%€30.41€20.28n/a15
Feb ’25€22.40
€23.68
+5.7%
10.2%€26.76€18.45n/a15
Jan ’25€22.60
€23.88
+5.7%
9.2%€27.48€20.15n/a15
Dec ’24€22.40
€23.91
+6.7%
11.0%€29.42€20.23n/a15
Nov ’24€21.20
€25.17
+18.7%
10.5%€30.28€20.82€20.0015
Oct ’24€22.80
€26.91
+18.0%
10.4%€32.36€23.80€21.4015
Sep ’24€25.60
€26.74
+4.5%
9.6%€31.02€22.81€19.6016
Aug ’24€26.80
€26.06
-2.7%
11.2%€30.96€20.03€21.8016
Jul ’24€25.00
€26.21
+4.9%
12.4%€34.82€20.16€20.8018
Jun ’24€22.20
€27.47
+23.7%
10.9%€35.56€22.46€22.4017
May ’24€24.40
€27.73
+13.7%
9.9%€34.77€22.87€22.6016
Apr ’24€24.40
€29.05
+19.1%
8.4%€35.39€23.28€23.6015
Mar ’24€27.60
€29.52
+7.0%
8.7%€35.82€23.57€23.4016
Feb ’24€29.00
€29.06
+0.2%
10.4%€36.76€22.98€22.4016
Jan ’24€25.80
€28.72
+11.3%
11.6%€37.44€23.40€22.6016
Dec ’23€26.40
€29.57
+12.0%
16.9%€46.07€24.00€22.4016
Nov ’23€27.20
€33.34
+22.6%
23.2%€58.93€25.40€21.2016

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Stanmore Resources

AU$2.8b

Engages in the exploration, development, production, and sale of metallurgical coal in Australia.

S0D

AU$1.82

7D

-4.2%

1Y

-18.0%

Arkema

€5.9b

Manufactures and sells specialty chemicals and advanced materials worldwide.

V1S

€78.00

7D

-1.9%

1Y

-16.1%

African Rainbow Minerals

R31.4b

Through its subsidiaries, operates as a diversified mining and minerals company in South Africa and Switzerland.

EB9

R8.25

7D

-11.8%

1Y

0.6%